Publications by authors named "Catalina Alamon"

Claim this Profile
E
Exploring the cell death mechanisms of cytotoxic [1,2,3]triazolylcarborane lead compounds against U87 MG human glioblastoma cells.
Catalina Alamón, Belén Dávila, Hugo Cerecetto, Marcos Couto

Chem Biol Drug Des· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Potential Boron Neutron Capture Therapy Agent Selectively Suppresses High-Grade Glioma: and Exploration.
Catalina Alamón, Belén Dávila, María Fernanda García, Susana Nievas, María Alejandra Dagrosa

Mol Pharm· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Substrate Recognition Properties from an Intermediate Structural State of the UreA Transporter.
Manuel Sanguinetti, Lucianna Helene Silva Santos, Juliette Dourron, Catalina Alamón, Juan Idiarte

Int J Mol Sci· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PD-1/PD-L1 blockade abrogates a dysfunctional innate-adaptive immune axis in critical β-coronavirus disease.
Maite Duhalde Vega, Daniela Olivera, Gustavo Gastão Davanzo, Mauricio Bertullo, Verónica Noya

Sci Adv· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The pathogenic role of c-Kit+ mast cells in the spinal motor neuron-vascular niche in ALS.
Mariángeles Kovacs, Catalina Alamón, Cecilia Maciel, Valentina Varela, Sofía Ibarburu

Acta Neuropathol Commun· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bimodal Therapeutic Agents Against Glioblastoma, One of the Most Lethal Forms of Cancer.
Marcos Couto, Catalina Alamón, Susana Nievas, Marina Perona, María Alejandra Dagrosa

Chemistry· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sunitinib-Containing Carborane Pharmacophore with the Ability to Inhibit Tyrosine Kinases Receptors FLT3, KIT and PDGFR-β, Exhibits Powerful In Vivo Anti-Glioblastoma Activity.
Catalina Alamón, Belén Dávila, María Fernanda García, Carina Sánchez, Mariángeles Kovacs

Cancers (Basel)· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
-
-Carboranyl- and Metallacarboranyl [1,2,3]triazolyl-Decorated Lapatinib-Scaffold for Cancer Therapy Combining Tyrosine Kinase Inhibition and Boron Neutron Capture Therapy.
Marcos Couto, Catalina Alamón, María Fernanda García, Mariángeles Kovacs, Emiliano Trias

Cells· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Carboranylanilinoquinazoline EGFR-inhibitors: toward 'lead-to-candidate' stage in the drug-development pipeline.
Marcos Couto, Catalina Alamón, Carina Sánchez, Belén Dávila, Marcelo Fernández

Future Med Chem· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Potent EGFR Inhibitors through the Incorporation of a 3D-Aromatic-Boron-Rich-Cluster into the 4-Anilinoquinazoline Scaffold: Potential Drugs for Glioma Treatment.
Marcos Couto, María Fernanda García, Catalina Alamón, Mauricio Cabrera, Pablo Cabral

Chemistry· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis